Chinese Firms Expand Solo Global Phase III Activity Including US Sites

Indicative Of Independent Growth

from 2024 to 2025
2024's seven global Phase III trials opened solely by Chinese firms was the second least since 2020. (Shutterstock)

More from China

More from Scrip Perspectives